Lack of efficacy of pegylated interferon monotherapy for hepatitis C in patients with end-stage renal disease on dialysis

Gastroenterology and Hepatology

Volumn 2, Issue 7, 2006, Pages 504-508

  Sauk, Jenny ^a   Jensen, Donald M ^a   Mohanty, Smruti R ^a   Reau, Nancy ^a   Reddy, K Gautham ^a   Te, Helen S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dialysis; End stage renal disease; Hepatitis C; Pegylated interferon; Renal failure

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MENTAL DISEASE; MONOTHERAPY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PSYCHOSIS; RELAPSE; RESPIRATORY TRACT DISEASE; TINNITUS; VIRUS LOAD; VOMITING; XEROSTOMIA;

EID: 33845941220     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345: 41-52.
2. Tokars JI, Finelli L, Alter MJ, et al. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial. 2004;17:310-19.
3. Batty DS, Jr., Swanson SJ, Kirk AD, et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant. 2001;1:179-184.
4. Bergman S, Accortt N, Turner A, et al. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis. 2005;45:684-689.
5. Dentico P, Volpe A, Buongiorno R, et al. Hepatitis C virus in hemodialysis patients. Nephron. 1992;61:307-308.
6. Hardy NM, Sandroni S, Danielson S, et al. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol. 1992;38:44-48.
7. Sanchez-Tapias JM. Nosocomial transmission of hepatitis C virus. J Hepatol. 1999;31(suppl 1):107-112.
8. Chan TM, Lok AS, Cheng IK. Hepatitis C in renal transplant recipients. Transplantation. 1991;52:810-813.
9. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10.
10. Gilli P, Moretti M, Soffritti S, et al. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs. 1990;13:737-741.
11. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896-902.
12. Pereira BJ. Renal transplantation in patients positive for hepatitis B or C (con). Transplant Proc. 1998;30:2070-2072.
13. Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-634.
14. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271-1277.
15. al-Wakeel J, Malik GH, al-Mohaya S, et al. Liver disease in dialysis patients with antibodies to hepatitis C virus. Nephrol Dial Transplant. 1996;11:2265-2268.
16. Caramelo C, Ortiz A, Aguilera B, et al. Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis. 1993;22:822-828.
17. Cisterne JM, Rostaing L, Izopet J, et al. Epidemiology of HCV infection: disease and renal transplantation. Nepbrol Dial Transplant. 1996;11 Suppl 4:46-47.
18. Haem J, Berrhoux P, Cecillon S, et al. HCV liver disease in renal transplantation: a clinical and histological study. Nephrol Dial Transplant. 1996;11(suppl 4):48-51.
19. Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:1452-1461.
20. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998;65:667-670.
21. Marhurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.
22. Diego JM, Roth D. Treatment of hepatitis C infection in patients with renal disease. Curr Opin Nephrol Hypertens. 1998;7:557-562.
23. Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol. 2005;3:S113-S117.
24. Heathcote EJ, Shiftman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.
25. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
26. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
27. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
28. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
29. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
30. Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat. 2001;8:287-292.
31. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant. 2001;16:193-195.
32. Russo MW, Goldsweig CD, Jacobson IM, et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98:1610-1615.
33. Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003;18:1071-1081.
34. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19:390-399.
35. Chatelut E, Rostaing L, Gregoire N, et al. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol. 1999;47:365-371.
36. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol. 2002;42:1109-1115.
37. Uchihara M, Izumi N, Sakai Y, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron. 1998;80:51-56.
38. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol. 1998;9:2344-2348.
39. Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther. 2004;20:123-124; author reply 124.
40. Sporea I, Sirli R, Golea O, et al. Peg-Interferon Alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Rom J Gastroenterol. 2004;13:99-102.
41. Teta D, Luscher BL, Gonvers JJ, et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant. 2005;20:991-993.
42. Pawa S. Patients with Chronic Hepatitis C and Chronic Renal Insufficiency or End Stage Renal Disease Respond Poorly to Interferon Monotherapy. Hepatology. 2004;40:332A-333A.
43. Luxon BA, Muir AJ, Heneghan MA. Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients. Hepatology. 2005;42:703A-704A.
44. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep. 2004;6:66-70.
45. Jeifers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708.
46. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271.
47. Potthoff A, Wiegand J, Luth JB, et al. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol. 2005;63:232-235.
48. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68:556-567.
49. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis. 2004;24(suppl 2):69-77.